14 Dec 2021 07:00
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Â
Confirmation of detection of Omicron variant
VISITECT® COVID-19 antigen test performs with the same high accuracy on the Omicron variant
Â
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, has been notified by its technology partner Mologic Ltd ("Mologic") that data from analysis on clinical samples, as well as in-silico analysis, show that the Mologic Covios® Ag lateral flow test, performs with the same high accuracy on the Omicron variant as it does with existing known variants.
Â
This is the same test that is manufactured and sold for professional use by Omega as the VISITECT® COVID-19 antigen test.
Â
Colin King, CEO, Omega Diagnostics, said: "We are very pleased be in a position to confirm that the VISITECT® COVID-19 antigen test is able to equally detect the Omicron variant, as well as other existing variants. We remain encouraged by emerging commercial opportunities for our VISITECT® COVID-19 Antigen test that we expect to be unlocked following relevant approval under CTDA regulations and CE-marking for home-use."
Â
Contacts:Â
Â
Omega Diagnostics Group PLC | www.omegadx.com |
Colin King, Chief Executive Officer | via Walbrook PR |
Chris Lea, Chief Financial Officer | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Edward Whiley (Corporate Finance) | |
Alice Lane/ Charlotte Sutcliffe (ECM) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Applegarth | Mob: 07584 391 303 |
Sam Allen | Mob: 07502 558 258 |
Â
Â
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.
www.omegadx.com
Â